Skip to main content

Ulcerative Colitis

Ulcerative Colitis
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

David Rubin
Conference Coverage
10/23/2026
David T. Rubin, MD
Dr Rubin presents the key takeaways from his lecture on positioning therapies for ulcerative colitis to optimize outcomes, which he delivered at the ACG Postgraduate Course in Nashville. 
Dr Rubin presents the key takeaways from his lecture on positioning therapies for ulcerative colitis to optimize outcomes, which he delivered at the ACG Postgraduate Course in Nashville. 
Dr Rubin presents the key...
10/23/2026
Advances in Inflammatory Bowel Disease Network
David Rubin
Conference Coverage
10/13/2026
David T. Rubin, MD
Dr Rubin reviews data from the QUASAR phase 3 trial of guselkumab in patients with ulcerative colitis, specifically looking at histologic remission, which he presented at the ACG Scientific Meeting in Nashville.
Dr Rubin reviews data from the QUASAR phase 3 trial of guselkumab in patients with ulcerative colitis, specifically looking at histologic remission, which he presented at the ACG Scientific Meeting in Nashville.
Dr Rubin reviews data from the...
10/13/2026
Advances in Inflammatory Bowel Disease Network
Conference Coverage
10/11/2026
Rebecca Mashaw
A study of Clostridioides difficile colonization in the microbiome of ulcerative colitis won an ACG Outstanding Research Award in the Infections and Microbiome Category at the American College of Gastroenterology Scientific Meeting.
A study of Clostridioides difficile colonization in the microbiome of ulcerative colitis won an ACG Outstanding Research Award in the Infections and Microbiome Category at the American College of Gastroenterology Scientific Meeting.
A study of Clostridioides...
10/11/2026
Advances in Inflammatory Bowel Disease Network
Maria Abreu
Research Insights
05/19/2026
Maria Abreu, MD
Dr Abreu recaps the results of a late breaking abstract from Digestive Disease Week on the DUET-UC study, which tested whether a combination of two advanced therapies showed an additive or synergistic effect in patients refractory ulcerative...
Dr Abreu recaps the results of a late breaking abstract from Digestive Disease Week on the DUET-UC study, which tested whether a combination of two advanced therapies showed an additive or synergistic effect in patients refractory ulcerative...
Dr Abreu recaps the results of a...
05/19/2026
Advances in Inflammatory Bowel Disease Network
Jean-Frederic Colombel
Expert Insights
05/06/2026
Jean-Frederic Colombel
Dr Colombel discusses his presentation at DDW 2026 on a post-doc analysis of the long-term outcomes of the LUCENT trial of mirikizumab, which showed that the IL-23p19 inhibitor achieved and maintained disease clearance for up to 4 years among...
Dr Colombel discusses his presentation at DDW 2026 on a post-doc analysis of the long-term outcomes of the LUCENT trial of mirikizumab, which showed that the IL-23p19 inhibitor achieved and maintained disease clearance for up to 4 years among...
Dr Colombel discusses his...
05/06/2026
Advances in Inflammatory Bowel Disease Network
Stephen Hanauer
Conference Coverage
12/12/2025
Stephen B. Hanauer, MD
A targeted, risk-stratified approach helps to ensure the best outcomes in treating ulcerative colitis, Dr Hanauer stated.
A targeted, risk-stratified approach helps to ensure the best outcomes in treating ulcerative colitis, Dr Hanauer stated.
A targeted, risk-stratified...
12/12/2025
Advances in Inflammatory Bowel Disease Network
Ed Loftus
Conference Coverage
12/12/2025
Edward V. Loftus, Jr., MD
Dr Loftus explains the importance of recognizing that patients with ulcerative colitis may have subclinical--and damaging--inflammation in the absence of symptoms .
Dr Loftus explains the importance of recognizing that patients with ulcerative colitis may have subclinical--and damaging--inflammation in the absence of symptoms .
Dr Loftus explains the...
12/12/2025
Advances in Inflammatory Bowel Disease Network
Vipul Jairath
Conference Coverage
11/05/2025
Vipul Jairath, MD
Dr Jairath discusses the phase 2B study results of icotrokinra, a novel, oral interleukin-23 peptide, for the treatment of moderately to severely active ulcerative colitis, which were presented at the ACG 2025 Scientific Meeting.
Dr Jairath discusses the phase 2B study results of icotrokinra, a novel, oral interleukin-23 peptide, for the treatment of moderately to severely active ulcerative colitis, which were presented at the ACG 2025 Scientific Meeting.
Dr Jairath discusses the phase...
11/05/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
08/04/2025
David T. Rubin, MD; Raymond Cross, MD
Host Raymond Cross, MD, discusses the updates in the American College of Gastroenterology guideline on managing ulcerative colitis with first author David Rubin, MD.
Host Raymond Cross, MD, discusses the updates in the American College of Gastroenterology guideline on managing ulcerative colitis with first author David Rubin, MD.
Host Raymond Cross, MD,...
08/04/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
05/09/2025
Edward L. Barnes
Guest host Sara Horst, MD, and Dr Edward Barnes discuss complications of ileal pouch-anal anastamosis surgery and whether recent use of antibiotics puts patients at risk of pouchitis.
Guest host Sara Horst, MD, and Dr Edward Barnes discuss complications of ileal pouch-anal anastamosis surgery and whether recent use of antibiotics puts patients at risk of pouchitis.
Guest host Sara Horst, MD, and...
05/09/2025
Advances in Inflammatory Bowel Disease Network